DAFNA Capital Management’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

DAFNA Capital Management’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-135,850	Closed	-$701K	–	88
2024 Q2	$701K	Hold	135,850	–	–	0.17%	69
2024 Q1	$727K	Sell	135,850 -79,035	-37%	-$547K	0.17%	64
2023 Q4	$1.67M	Sell	214,885 -50,993	-19%	-$175K	0.4%	49
2023 Q3	$1.05M	Hold	265,878	–	–	0.33%	56
2023 Q2	$838K	Hold	265,878	–	–	0.23%	55
2023 Q1	$710K	Hold	265,878	–	–	0.21%	55
2022 Q4	$955K	Hold	265,878	–	–	0.27%	52
2022 Q3	$1.71M	Buy	+265,878	New	+$2.16M	0.46%	45

Other funds holding SYRS

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

DAFNA Capital Management's SYRS Position: Q3 2024 in Review

DAFNA Capital Management sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q3 2024, closing a stake of 135,850 shares — an estimated $701K sold.

DAFNA Capital Management first reported a position in SYRS in Q3 2022 and held it in 8 quarters. The position peaked at $1.71M in Q3 2022. 65 funds tracked by Wall St. Rank hold SYRS as of Q3 2024.

DAFNA Capital Management reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
DAFNA Capital Management sold 135,850 Syros Pharmaceuticals, Inc. Common Stock shares in Q3 2024, an estimated $701K.
DAFNA Capital Management first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2022 and held it in 8 quarters.
DAFNA Capital Management's Syros Pharmaceuticals, Inc. Common Stock position peaked at $1.71M in Q3 2022.
65 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q3 2024.

Based on DAFNA Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.